ELV Stock Analysis
💡 Quick Answer
Across 4 APEX technical signals, ELV is currently split between bullish and bearish readings — 0 bullish, 0 bearish as of 2026-06-11. Run a live analysis to see the current composite score.
ELV has ATR of 2-4% and is considered the highest-quality large-cap health insurer after UNH. Post-earnings moves of 5-8% are typical.
Elevance Health (formerly Anthem) is the second-largest U.S. health insurer by membership, serving 45+ million people through commercial, Medicaid, and Medicare plans. Its affiliated Blue Cross Blue Shield plans operate in 14 states. Some of the most commercially valuable health insurance territories in the U.S. Elevance is diversifying its business through CarelonRx (its PBM and pharmacy services business) and Carelon Services (care management and health services), following the vertical integration playbook pioneered by UnitedHealth Group.
Why Do Traders Watch ELV?
ELV has ATR of 2-4% and is considered the highest-quality large-cap health insurer after UNH. Post-earnings moves of 5-8% are typical. ELV's Blue Cross brand provides pricing power in commercial insurance that other insurers lack, and its Medicaid business creates a stable government-contracted revenue stream. The primary trading risk is Medicaid redetermination cycles. When states re-verify Medicaid eligibility and disenroll ineligible members, reducing Elevance's membership and revenue.
Is ELV a Buy Right Now? Current Signal Readings
Elevance's Blue Cross Blue Shield brand commands pricing premiums in its 14-state territory that non-BCBS insurers cannot match. When commercial premium increases exceed medical cost trend. The ideal environment. ELV's operating margin expands materially. Monitor annual employer health plan renewal rate increases (typically 8-12%) against medical trend (typically 7-9%) for margin direction.
Elevance is the second-largest Medicaid managed care insurer, serving 10+ million Medicaid beneficiaries. State-by-state Medicaid redetermination cycles. Where states recheck eligibility after the COVID-era continuous enrollment ended. Have reduced Medicaid membership. Tracking state-level Medicaid enrollment data monthly provides advance warning of ELV's government revenue trajectory.
ELV's BCBS pricing power creates more stable RSI patterns than peers with higher MA exposure. RSI dips to 42-46 during broad healthcare insurer selloffs. Driven by Medicare Advantage concerns that affect HUM and UNH more directly. Have been reliable ELV entry points as investors differentiate its commercial-heavy mix from MA-concentrated peers.
Elevance is replicating UnitedHealth's Optum model. Building Carelon into a healthcare services and technology business separate from insurance premium revenue. Carelon's revenue growing to 20%+ of total revenue at higher margins than insurance would compress ELV's valuation discount to UNH over 3-5 years. Track Carelon external revenue (sales to non-Elevance customers) as the key diversification signal.
📋 ELV Key Stats for Traders
APEX combines RSI, MACD, Fibonacci, Volume, and 4 more signals into one composite score in under 30 seconds.
Analyze ELV Free →